FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics Inc. (NASDAQ:FBLG) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 135,591 shares, a decrease of 42.9% from the May 14th total of 237,640 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average daily volume of 99,753 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in FBLG. AQR Capital Management LLC bought a new position in shares of FibroBiologics in the first quarter worth about $29,000. XTX Topco Ltd raised its stake in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares during the period. Marshall Wace LLP bought a new stake in FibroBiologics during the 2nd quarter valued at approximately $49,000. Cerity Partners LLC raised its stake in FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares during the period. Finally, Jane Street Group LLC bought a new stake in FibroBiologics during the 2nd quarter valued at approximately $60,000.

Analyst Upgrades and Downgrades

FBLG has been the topic of a number of recent research reports. Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and issued a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a research report on Thursday, March 26th. Maxim Group cut shares of FibroBiologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Weiss Ratings downgraded shares of FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, June 1st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $74.00.

FibroBiologics Stock Down 3.4%

NASDAQ FBLG opened at $0.93 on Friday. The stock’s 50-day moving average price is $1.23 and its 200-day moving average price is $4.14. FibroBiologics has a 52 week low of $0.91 and a 52 week high of $17.20. The company has a market capitalization of $4.85 million, a P/E ratio of -0.13 and a beta of 1.13.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) EPS for the quarter, hitting the consensus estimate of ($1.33). Research analysts anticipate that FibroBiologics will post -4.01 EPS for the current year.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.